Trv Gp Iv, LLC Tango Therapeutics, Inc. Transaction History
Trv Gp Iv, LLC
- $206 Million
- Q1 2024
A detailed history of Trv Gp Iv, LLC transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Trv Gp Iv, LLC holds 19,201,475 shares of TNGX stock, worth $165 Million. This represents 73.88% of its overall portfolio holdings.
Number of Shares
19,201,475
Previous 19,363,975
0.84%
Holding current value
$165 Million
Previous $192 Million
20.47%
% of portfolio
73.88%
Previous 77.88%
Shares
2 transactions
Others Institutions Holding TNGX
# of Institutions
127Shares Held
88.8MCall Options Held
2KPut Options Held
1.6K-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$114 Million3.02% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$70.3 Million3.39% of portfolio
-
Nextech Invest Ag5.53MShares$47.5 Million8.22% of portfolio
-
Southpoint Capital Advisors LP New York, NY5.28MShares$45.3 Million0.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.32MShares$37.1 Million0.02% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $756M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...